tbuckley/cabot-search huggingface dataset:
Identification of urinary biomarkers to distinguish tumor bearing and control rats in the methylnitrosourea (MNU) – induced model of mammary carcinogenesis: use of label-free, comparative, ultra-high resolution nano-LC mass spectrometry.
Authors: RR Townsend, H Rohrs, R Leduc, Y Yi, R Yao, JP Malone, P Edrman-Gilmore, CJ Grubbs, M You, RA Lubet
Journal: Cancer Research (2009)

Abstract Abstract #1109 In the MNU induced model of mammary cancer, rats given a single dose of MNU (75 mg/kg BW), via the jugular vein, at 50 days of age develop multiple ER+ mammary cancers. These cancers appear similar to highly differentiated ER+ human breast cancers, and have been shown to be sensitive to many of the same chemotherapeutic agents that are effective in women. When a female rat developed its first palpable cancer, it was placed in a metabolic cage and urine collected overnight on dry ice. The urine from these rats were compared to those obtained from control rats. Using a new sample preparation protocol, peptides were prepared from the urines of control (n = 4 individual animals) and rats bearing induced mammary tumors (n = 4). The peptide pools were analyzed using nano-LC-LTQ-FT-MS. The 8 LC-MS analyses were aligned and the integrated accurate mass signals were quantified using Rosetta ElucidatorTM software. The ion currents from 4430 peptides (charge state &amp;gt; +2) were analyzed between the two groups using ANOVA. Two hundred and twenty nine peptides were found to be significantly different (P&amp;lt; 0.01) between the two groups, with clear distinction between the urines from control and experimental animals being observed using hierarchical clustering and principal component analysis. The protein identifications that were significantly increased in the tumor-bearing urines were confirmed by targeted tandem mass spectrometry. Further studies relating the altered expression of these peptides to differences in tumor size, the effects of therapeutic agents, etc will also be presented. Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 1109.
A Giant Aneurysm of the Anterior Communicating Artery
Authors: Nirav J Patel, Aristotelis Filippidis
Journal: New England Journal of Medicine (2015)

A 55-year-old man presented with a 3-year history of visual impairment and personality changes. His sister had died after an intracerebral aneurysmal rupture. Examination revealed poor visual acuity in the right eye with a field defect, as well as impaired neurocognition.
A Creeping Suspicion
Authors: Casey M. Rice, Siddhartha Yadav, Bobby Boyanton, Prajan Subedi, Jeffrey Band
Journal: New England Journal of Medicine (2014)

A 51-year-old woman was brought to the emergency room after the development of nonsensical speech, including confused word choices and difficulty with naming objects and counting. Her husband noted that she had reported headache, nausea, vomiting, and fatigue the previous day.
Endoscopic resection of duodenal adenomas: endoscopic mucosal resection or endoscopic submucosal dissection?
Authors: Shai Friedland
Journal: Endoscopy (2015)

Although the incidence of malignant duodenal neoplasms is low, duodenal adenomas are precursor lesions to cancer [1] and endoscopic resection is therefore justified if it can be performed safely. Multiple reports have demonstrated that endoscopic mucosal resection (EMR) of nonampullary duodenal adenomas – typically performed by standard snare polypectomy after submucosal fluid injection – yields acceptable results with regard to both safety and efficacy. Delayed bleeding is the most common complication of duodenal EMR, occurring in 0 – 30 % of cases [2] [3] [4] [5]. Endoscopic treatment utilizing clip placement or cauterization is usually effective, although many cases also resolve spontaneously [2]. Perforation is a rare complication of EMR, occurring at a rate of 0 – 3 % in most series. Most perforations occur with resection of larger lesions: for example, in one report there were no perforations in 31 resections of lesions < 30 mm compared with two perforations in 19 lesions ≥ 30 mm [6]. A limitation of EMR is recurrence of lesions on follow-up endoscopy, which is observed in 0 – 37 % of cases [7]. Although data are sparse, endoscopic treatment is successful for most recurrences [7].
Risk of Cirrhosis and Primary Liver Cancer in Alpha<sub>1</sub>-Antitrypsin Deficiency
Authors: Sten Eriksson, Joyce Carlson, Ramon Velez
Journal: New England Journal of Medicine (1986)

Previous reports have suggested an association between homozygous alpha 1-antitrypsin deficiency, cirrhosis, and primary liver cancer. To assess the risk of these complications we conducted a retrospective study based on 17 autopsied cases of alpha 1-antitrypsin deficiency identified during the period 1963 to 1982 in the city of Malmö, Sweden. During the study period, autopsies were performed in 38,250, or 68.2 percent, of all patients in the city who died. From the homozygote frequency in the population, 21 of these were expected to have alpha 1-antitrypsin deficiency. The disease had been diagnosed in 20, and autopsies had been performed in 17 (1 child and 16 adults). Each autopsied case was matched with four controls selected from the same autopsy register, and the Mantel-Haenszel odds ratio (ORmh) was calculated. The results indicated a strong relation between alpha 1-antitrypsin deficiency and cirrhosis (ORmh = 7.8; 95 percent confidence limits, 2.4 to 24.7) and primary liver cancer (ORmh = 20; 95 percent confidence limits, 3.5 to 114.3). When data were stratified according to sex, these associations were statistically significant only for male patients. We conclude that men with alpha 1-antitrypsin deficiency may be at higher risk for cirrhosis and primary liver cancer. The apparent male predominance suggests the additive effects of exogenous factors.
Distinct myeloid progenitor–differentiation pathways identified through single-cell RNA sequencing
Authors: Roy Drissen, Natalija Buza-Vidas, Petter Woll, Supat Thongjuea, Adriana Gambardella, Alice Giustacchini, Elena Mancini, Alya Zriwil, Michael Lutteropp, Amit Grover, Adam Mead, Ewa Sitnicka, Sten Eirik W Jacobsen, Claus Nerlov
Journal: Nature Immunology (2016)
Abstract 929: Caboxylic acid esters as inhibitors of the MEK1/2 and MEK5 signaling cascades.
Authors: Jane E. Cavanaugh, Darlene A. Monlish, Suravi Chakrabarty, Si Qin, Patrick T. Flaherty
Journal: Cancer Research (2013)

Abstract The purpose of the current study is to examine how structural variation on methyl anthranilates can differentially affect specific branches of the MAPK signaling cascade. The specific goal is to correlate the role of MEK1/2 versus MEK5 in breast cancer proliferation and migration modeled by the profile of pERK isoforms in treated BT-474 (ER+/PR+/HER2high) and MDA-MB-231 (ER−/PR−/HER2low) human breast cancer cell lines. The MAPK signaling pathway is a complex interconnected signaling cascade activated by extracellular stimuli, including growth factors, cytokines, and mechanical and chemical stressors, to elicit appropriate cellular responses including cell survival, proliferation, differentiation, and apoptotic cell death. The interconnected nature of these pathways permits a single external stimulus to be interpreted in the context of the immediate metabolic demands of the cell. The singularly specific and parallel event is phosphorylation of ERK by its corresponding activating kinase or MEK. In the course of examining small molecules with the design goal of developing selective inhibitors of the MEK5 isoform, we identified a simple substituted methyl anthranilate derivative that unexpectedly and specifically inhibited ERK1/2 activation but had little effect on ERK5 activation. We subsequently explored structural variations and prepared structure assisted new compounds from this initial find. In the BT-474 and MDA-MB-231 cell lines, western blot analysis was performed to determine the expression and activation of ERK1/2 and ERK5 following treatment with the novel MEK-specific inhibitors. An MTT assay was used to assess changes in cell proliferation following kinase inhibition, while scratch and invasion assays were performed to assess the effect of the carboxylic acid esters on cell migration and invasion in these cell lines. The data obtained from these studies indicate methyl anthranilate derivatives warrant further investigation as potential inhibitors of tumor proliferation and migration in breast cancer. Citation Format: Jane E. Cavanaugh, Darlene A. Monlish, Suravi Chakrabarty, Si Qin, Patrick T. Flaherty. Caboxylic acid esters as inhibitors of the MEK1/2 and MEK5 signaling cascades. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 929. doi:10.1158/1538-7445.AM2013-929
Abstract 1166: Inhibition of tumor growth in mouse models of cancer by systemic delivery of tumor suppressor miRNAs
Authors: David Brown, Chris Daige, Jason Wiggins, Kevin Kelnar, Lynnsie Ruffino, Michael Omotola, Jane Zhou, Andreas Bader
Journal: Cancer Research (2011)

Abstract Tumor suppressor miRNAs represent an intriguing new class of biomolecules that might be developed into therapeutic candidates for cancer. Based upon its involvement in the p53 pathway and its capacity to regulate cell cycle and apoptosis via multiple oncogenic pathways, miR-34 might be the most intriguing of the tumor suppressor miRNAs. We have developed mimics of the miR-34 tumor suppressor that have been tested for efficacy using xenograft and transgenic mouse models of cancer. When complexed with an effective delivery agent, tail-vein injected miR-34 mimics have proven capable of inhibiting the growth and metastasis of mature tumors. When delivered systemically to BalbC mice, the same complexed miR-34 mimics fail to incease the serum levels of liver, kidney, and heart toxicity markers. Systemically delivered miR-34 mimics also failed to induce cytokines in mice. The development of miR-34 mimics with enhanced pharmacokinetic profiles and a systemic delivery formulation that can be manufactured under cGMP conditions are underway. Preclinical efficacy, PK/PD, and rodent safety data will be presented. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 1166. doi:10.1158/1538-7445.AM2011-1166
NEUTROPHIL-DERIVED MICROPARTICLES ARE RELEASED INTO THE CORONARY CIRCULATION FOLLOWING CORONARY INTERVENTION IN ACUTE CORONARY SYNDROME PATIENTS
Authors: Jennifer Barraclough, Gonzalo J. Martínez, Shirley Nakhla, Vivian Kienzle, Stacy Robertson, Ziad Mallat, David Celermajer, Sanjay Patel
Journal: Journal of the American College of Cardiology (2016)
Case 7-2006
Authors: J. Kimo Takayesu, Hasan Bazari, Michael Linshaw
Journal: New England Journal of Medicine (2006)

A 47-year-old man was transferred to the emergency department because of altered mental status and acute renal failure. Approximately 13 hours earlier, lethargy had developed that progressed to unresponsiveness. The airway had been intubated and acidosis and an elevated creatinine level noted. A generalized tonic–clonic seizure occurred; the results of toxicologic screening of the serum and urine were negative, and a urine specimen contained numerous needle-shaped crystals.
Disseminated<i>Penicillium marneffei</i>Infection in a Patient with AIDS
Authors: K E Nelson, T Sirisanthana
Journal: New England Journal of Medicine (2001)

Figure 1. A 29-year-old man from northern Thailand had a three-week history of recurrent fever (a temperature of up to 40°C), generalized weakness, poor appetite, and weight loss. One week before hospitalization, papular skin lesions developed on his face (Panel A), chest, and arms, which enlarged and became umbilicated. He was found to be positive for the human immunodeficiency virus on enzyme-linked immunoassay but had not previously had an acquired immunodeficiency syndrome–defining illness. He was treated for a disseminated Penicillium marneffei infection with intravenous amphotericin B for two weeks, and the fever and skin lesions resolved. Therapy with oral itraconazole . . .
SLEEP APNEA RISK AND LETHAL VENTRICULAR ARRHYTHMIAS IN CONGESTIVE HEART FAILURE PATIENTS WITH IMPLANTABLE CARDIOVERTER DEFIBRILLATORS
Authors: Nchang Taka, Demilade Adedinsewo, Sivakumar Kalaivani, Punita Kaveti, Maihemuti Axiyan, Pradyumna Agasthi, Kyra Clark, Elizabeth Ofili, Rachel Harris
Journal: Journal of the American College of Cardiology (2016)
FRI0537 Update on the Juvenile Systemic Sclerosis Inception Cohort Www.Juvenile-Scleroderma.Com
Authors: I. Foeldvari, A. Wierk, T. Avcin, J. Brunner, R. Cimaz, T. Kallinich, M.M. Katsikas, Y. Uziel, M.T. Terreri, M. Kostic, D. Nemcova, F. Sztajnbok, K. Minden, J. Müller, I. Kone-Paut
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> Juvenile systemic sclerosis (jSSc) is a orphan autoimmune disease. Currently only retrospective data is existing without a standardized assessment regarding the organ involvement and evolvement of the disease. Our project is the first projects, where prospectively and with a standardized assessment data of early jSSc patients are collected. <h3>Objectives</h3> To learn about the evolvement of juvenile systemic sclerosis <h3>Methods</h3> Patients with less the 18 months of disease duration, after the first Non-Raynaud symptomatic, are prospectively assessed, using the proposed standardized patient assessment protocol. <h3>Results</h3> We report the characteristics of the patients at 0, at 6 and 12 months of follow up. We present date on 24 patients. The mean follow up of the patients in the cohort are 3.4 years. No patient died during the follow up. Eighteen of the 24 patients were female. The mean age of the onset of Raynaud symptomatic was 11.2 years, the youngest 4.2 years old. The mean age at the onset of the non-Raynaud symptomatic were 11.7 years. 20 of the 24 have diffuse subtype, 5 of them have an overlap symptomatic, two of them associated with diffuse subtype. ANA positive were 19, and 6 of them were anti-Scl 70 positive. None of them was anticentromere positive The mean modified Rodnan Skin Score was at timepoint 0, 6 and 12 month 19.4, 15.7 (n=19) and 15.6. (n=13). Raynaud9s Phenomen occurred in 20/23 at time point 0 and 14 of 19 at time point 6 months and 10 of 15 at 12 months. 16 of 23 of them have capillary changes at time point 0, 9 of 18 in m6 and 7 of 14 in m12. 7 of them have already ulcerations at time point zero, 9 of 18 at month 6 and 4 of 10 at months 12. 13 of them have cardiopulmonary involvement, at time point zero already, 8 of them have interstitial lung disease. 4 of 19 have cardiopulmonary involvement in month 6 and 6 of 16 in month 12. Two of them have renal involvement at time point 0 and 3 at time point 6 and 12 months. 9 of 23 had gastrointestinal involvement, and 5 of them oesophageal involvement at time point zero, 3 from 18 at time point month 6 and 5 of 16 at time point 12 months. Twenty of 23 have musculoskeletal involvement 17 of 19 In month 6 and 15 of 16 at time point 12 months. <h3>Conclusions</h3> We present the data on the first 24 prospectively assessed patients with jSSc. The current recruitment data confirms that pediatric patients are different from the adult patients. Unfortunately despite the prospective data collection, we miss some data. We are only at the first phase of this project and hope to recruit up to 50 patients and follow them prospectively over the next 5 years at least. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.5053
OP0009-HPR Development and Implementation of A Musculoskeletal Ultrasound Training Program for Nurses
Authors: B. Jakobsen, N.H. Kildal, H.S. Koksvik
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> Musculoskeletal ultrasound (MSUS) has become the first choice imaging investigation for the evaluation of musculoskeletal diseases. MSUS has traditionally been a task for medical doctors (MD). Over the last 10 years there have been an increasing number of extended roles for nurses in rheumatology care. From being a traditional care provider, the rheumatology nurses in Norway have become more independent and have taken on new roles in monitoring patients. The traditional joint count has become a standard assessment performed by nurses as they have taken on new roles. To enhance the role of the rheumatology nurse they are now trained to perform MSUS by a newly developed training program. There is no European certification to perform MSUS in rheumatology today; but there are different courses available. It is recommended by the European Federation of Societies for Ultrasound in Medicine and Biology (EFSUMB), that consideration is to be given to the setting up of suitable training programmes in order to ensure that ultrasound operators are properly trained for the job. <h3>Objectives</h3> To develop a training program for nurses in MSUS. <h3>Methods</h3> The training program is developed using the recommendations for the content and conduct of EULAR musculoskeletal ultrasound courses. Eight rheumatology nurses with experience in individual nursing consultations were included in the training program. The training program was drawn up in collaboration with the Rheumatology Department at St. Olavs Hospital and the Radiographic Institute at the Sør-Trøndelag University College. The complete program includes: – University course of 15 ECTS including theoretical, technical and practical education with expert supervisors, extensive training at a rheumatology department of 18 days with expert supervisors – EULAR basic MSUS course – The British Society of Rheumatology basic ultrasound course – Visits to other expert centres on MSUS in Europe. – During the implementation of MSUS in individual nursing consultations an expert supervisor was available for questions and expert opinion. <h3>Conclusions</h3> A formal education in collaboration with a clinical department and a university college seems to be of high theoretical and practical relevance for nurses to obtain appropriate education and skills in MSUS. MSUS performed by trained nurses seems to be of high quality. Seven of the eight nurses are using MSUS to monitor and assess disease activity in their clinical setting today. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.5063
ED-35 * PRIMARY SPINAL CORD MELANOMA (PSCM): A CASE REPORT AND LITERATURE REVIEW
Authors: O. Vyas, K. Arkun, L. Taylor
Journal: Neuro-Oncology (2014)

INTRODUCTION: PSCM is exceedingly rare, comprising 1% of all melanomas. Unlike their cutaneous counterparts; the origin and clinical characteristics of these malignancies is poorly characterized. Mutations in GNAQ have been implicated in non-cutaneous melanocytic tumors. We present a case of PSCM and review the literature, with a focus on intramedullary PSCMs. CASE REPORT: A 64-year-old woman presented with patchy dysesthesias in the right leg from L1-S3 followed by weakness in the left lower extremity. Spinal MRI showed a large intramedullary mass at T9-T10. Biopsy confirmed PSCM. Clinical examination and whole-body PET were unremarkable for systemic malignancy. GNAQ mutation analysis pending. METHODS: The patient's clinical, radiographic, and pathologic evaluation led to a detailed exploration of the topic, including a review of the case literature and their references. Cases that met Hayward's criteria and were intramedullary, from the first report in 1906 to the present, were included. REVIEW: 34 cases were consistent with PSCM. 21 (63%) were female. The median age was 62. Symptoms were progressive over months. The median duration of symptoms prior to presentation was 12 months. Survival from the time of presentation varied greatly from <1 month to 13 years, with a median of 12 months. The anatomic distribution was predominantly thoracic (25, 74%), with the remainder of lesions in the cervical spine (9, 26%). A consistent pattern of imaging is evident; almost all tumors demonstrated hyperintensity on T1 weighted imaging. T2 imaging demonstrated more heterogeneous characteristics. CONCLUSION: Presentation of this disease is insidious in nature and presents with months of progressive neurologic deficits. Tumors are typically located in thoracic spine with characteristic imaging findings. GNAQ oncogene testing is pending and may indicate a distinct underlying biology to PSCM compared to cutaneous melanoma. Awareness may encourage surgical intervention, which is often delayed given the high risk of operation.
Commercial assays have high false positive rate
Authors: J. Bendig, V. Meurisse, S. Chambers
Journal: BMJ (1995)

Commercial assays have high false positive rate EDITOR,-We agree with Philip Rice and colleagues' advice that immunocompromised patients (including all patients taking steroids) who claim not to have had chickenpox previously or are uncertain whether they have had it should be tested for antibodies to varicella zoster virus.'We advise caution, however, with regard to use of the latex agglutination assay.Over the past 19 months we received 32 serum
Treatment of Hematoma of the Nasal Septum
Authors: Jason I. Kass, Berrylin J. Ferguson
Journal: New England Journal of Medicine (2015)

A hematoma of the nasal septum may deprive the septal cartilage of its blood supply and lead to permanent sequelae unless it is drained promptly. This video demonstrates how to incise, drain, and pack a nasal septal hematoma.
Treatment of X-Linked Severe Combined Immunodeficiency by in Utero Transplantation of Paternal Bone Marrow
Authors: Alan W. Flake, Maria-Grazia Roncarolo, Jennifer M. Puck, Graza Almeida-Porada, Mark I. Evans, Mark P. Johnson, Estaban M. Abella, Duane D. Harrison, Esmail D. Zanjani
Journal: New England Journal of Medicine (1996)

EVERE combined immunodeficiency is a congenital syndrome due to various genetic abnormalities that cause susceptibility to infection, failure to thrive, lymphoid hypoplasia, very low levels of T lymphocytes, and hypogammaglobulinemia. 1,2Untreated, the disorder is usually fatal within the first year of life.We report the successful treatment of a fetus with the X-linked variant of severe combined immunodeficiency by the in utero transplantation of paternal bone marrow that was enriched with hematopoietic cell progenitors.